Market Place
Sourcing Support
Amylyx Publishes AMX0035 Data On Alzheimer`s Biomarkers
12 Aug 2024 //
BUSINESSWIRE
Amylyx stock slips 6% after phase 2 rare disease data drop
11 Apr 2024 //
FIERCE BIOTECH
Amylyx to pull failed ALS drug Relyvrio from market, cut 70% of staffers
05 Apr 2024 //
PRESS RELEASE
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
09 Mar 2024 //
PRESS RELEASE
RELYVRIO® and AMX0114 Data to be Presented at 34th Symposium on ALS/MND
27 Nov 2023 //
BUSINESSWIRE
Amylyx`s ALS drug Albrioza rebuffed by EU regulator—again
14 Oct 2023 //
FIERCE PHARMA
Amylyx to appeal EMA panel recommendation against ALS drug
24 Jun 2023 //
ENDPTS
Amylyx`s Relyvrio pulls in $71M in revenue
12 May 2023 //
ENDPTS
Amylyx welcomes former Alnylam exec; Amarin plugs in an interim chief
21 Apr 2023 //
ENDPTS
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Amylyx`s ALS drug finally approved by FDA
30 Sep 2022 //
FIERCEPHARMA
Amylyx Announces Donated CENTAUR Trial Data Available to Advance Science in ALS
14 Sep 2022 //
PRESS RELEASE
Amylyx Announces Donated CENTAUR Trial Data Available to Help Advance Science
14 Sep 2022 //
BUSINESSWIRE
Amylyx Announces Publication of Data Showing Potential Effect of AMX0035
12 Sep 2022 //
BUSINESSWIRE
Amylyx Announces FDA Advisory Committee Supports Approval of AMX0035
07 Sep 2022 //
BUSINESSWIRE
Amylyx Announces Posting of Briefing Documents for FDA Meeting on AMX0035
02 Sep 2022 //
BUSINESSWIRE
Amylyx Pharmaceuticals Reports Second Quarter 2022 Financial Results
11 Aug 2022 //
BUSINESSWIRE
Amylyx Announces FDA Will Reconvene to Review New Drug Application
03 Aug 2022 //
BUSINESSWIRE
Amylyx Pharmaceuticals Stock Trading Halted Today
30 Mar 2022 //
BUSINESSWIRE
Amylyx Pharma Announces Posting of Briefing Documents for FDA Advisory Committee
28 Mar 2022 //
BUSINESSWIRE
Amylyx Announces EMA Validation of MAA for AMX0035 in ALS
25 Feb 2022 //
BUSINESSWIRE
CNDR, Amylyx Partner on Real-World Evidence Generation for Novel Therapy in ALS
03 Feb 2022 //
BUSINESSWIRE
Amylyx Pharmaceuticals Submits MAA for AMX0035 for the Treatment of ALS
04 Jan 2022 //
BUSINESSWIRE
Amylyx Pharmaceuticals to Submit NDA for AMX0035 for ALS
15 Sep 2021 //
BUSINESSWIRE
Amylyx Pharmaceuticals Announces Phase 2 Study of AMX0035
04 Oct 2019 //
BUSINESSWIRE
Orion takes repurposed heart drug into phase 3 for ALS
06 Jul 2018 //
FIERCE BIOTECH
Canadian advance in solving brain disease
14 Sep 2015 //
RCI
Finding a way forward in the fight against prion disease
03 Sep 2015 //
EUREKALERT
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.